Volume 33, Issue 6 pp. 795-802
Original Article

Progressive ataxia and myoclonic epilepsy in a patient with a homozygous mutation in the FOLR1 gene

Belén Pérez-Dueñas

Corresponding Author

Belén Pérez-Dueñas

Departament of Neurology, Hospital Sant Joan de Déu, Passeig Sant Joan de Dèu, 2, Esplugues, Barcelona, 08950 Spain

Centre for Biomedical Research on Rare Diseases (CIBERER), ISCIII, Barcelona, Spain

Telephone: +34-93-2804000, Fax: +34-93-2033959, [email protected]

Search for more papers by this author
Claudio Toma

Claudio Toma

Department of Genetics, Faculty of Biology, University of Barcelona, Barcelona, Spain

Centre for Biomedical Research on Rare Diseases (CIBERER), ISCIII, Barcelona, Spain

Search for more papers by this author
Aida Ormazábal

Aida Ormazábal

Department of Biochemistry, Hospital Sant Joan de Déu, Barcelona, Spain

Centre for Biomedical Research on Rare Diseases (CIBERER), ISCIII, Barcelona, Spain

Search for more papers by this author
Jordi Muchart

Jordi Muchart

Department of Neuroradiology, Hospital Sant Joan de Déu, Barcelona, Spain

Search for more papers by this author
Francesc Sanmartí

Francesc Sanmartí

Departament of Neurology, Hospital Sant Joan de Déu, Passeig Sant Joan de Dèu, 2, Esplugues, Barcelona, 08950 Spain

Epilepsy Unit, Hospital Sant Joan de Déu, Barcelona, Spain

Search for more papers by this author
Georgina Bombau

Georgina Bombau

Department of Genetics, Faculty of Biology, University of Barcelona, Barcelona, Spain

Search for more papers by this author
Mercedes Serrano

Mercedes Serrano

Departament of Neurology, Hospital Sant Joan de Déu, Passeig Sant Joan de Dèu, 2, Esplugues, Barcelona, 08950 Spain

Centre for Biomedical Research on Rare Diseases (CIBERER), ISCIII, Barcelona, Spain

Search for more papers by this author
Angels García-Cazorla

Angels García-Cazorla

Departament of Neurology, Hospital Sant Joan de Déu, Passeig Sant Joan de Dèu, 2, Esplugues, Barcelona, 08950 Spain

Centre for Biomedical Research on Rare Diseases (CIBERER), ISCIII, Barcelona, Spain

Search for more papers by this author
Bru Cormand

Bru Cormand

Department of Genetics, Faculty of Biology, University of Barcelona, Barcelona, Spain

Centre for Biomedical Research on Rare Diseases (CIBERER), ISCIII, Barcelona, Spain

Institute of Biomedicine of the University of Barcelona (IBUB), Barcelona, Spain

Search for more papers by this author
Rafael Artuch

Rafael Artuch

Department of Biochemistry, Hospital Sant Joan de Déu, Barcelona, Spain

Centre for Biomedical Research on Rare Diseases (CIBERER), ISCIII, Barcelona, Spain

Search for more papers by this author
First published: 21 September 2010
Citations: 43

Communicated by: Nenad Blau

Competing interest: None declared.

Electronic Supplementary Material:

The online version of this article (doi:10.1007/s10545-010-9196-1) contains supplementary material, which is available to authorized users.

Abstract

Several unrelated disorders can lead to 5-methyltetrahydrofolate (5MTHF) depletion in the cerobrospinal fluid (CSF), including primary genetic disorders in folate-related pathways or those causing defective transport across the blood-CSF barrier. We report a case of cerebral folate transport deficiency due to a novel homozygous mutation in the FOLR1 gene, in an effort to clarify phenotype–genotype correlation in this newly identified neurometabolic disorder. A previously healthy infant developed an ataxic syndrome in the second year of life, followed by choreic movements and progressive myoclonic epilepsy. At the age of 26 months, we analyzed CSF 5MTHF by HPLC with fluorescence detection and conducted magnetic resonance (MR) imaging and spectroscopy studies. Finally, we performed mutational screening in the coding region of the FOLR1 gene. MR showed a diffuse abnormal signal of the cerebral white matter, cerebellar atrophy and a reduced peak of choline in spectroscopy. A profound deficiency of CSF 5MTHF (2 nmol/L; NV 48-127) with reduced CSF/plasma folate ratio (0.4; NV 1.5-3.5) was highly suggestive of defective brain folate-specific transport across the blood-CSF/brain barrier. Mutation screening of FOLR1 revealed a new homozygous missense mutation (p.Cys105Arg) that is predicted to abolish a disulfide bond, probably necessary for the correct folding of the protein. Both parents were heterozygous carriers of the same variant. Mutation screening in the FOLR1 gene is advisable in children with profound 5MTHF deficiency and decreased CSF/serum folate ratio. Progressive ataxia and myoclonic epilepsy, together with impaired brain myelination, are clinical hallmarks of the disease.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.